← All candidates
87 insider filings on record.
87 filings on record.
ARWRARROWHEAD PHARMACEUTICALS, INC.
NasdaqGS · Healthcare · $10.31B
$80.67
-2.63% · Sep 14
87 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 59 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what ARWR ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$10.31B
Float
122.4M
87% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
15.4
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
82 more transactions on Pro →Context
Wall St
$88.17 avg target
+9.3% vs today · 12 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.93 act+$0.18
Q4 '25$0.22 act+$0.59
Q3 '25−$0.18 act−$0.02
Q2 '25−$1.26 act−$0.16
Coverage
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains TractionMarketBeat · 06-05Arrowhead Data On Plozasiran Expands Cardiometabolic Opportunity And Investor FocusSimply Wall St. · 05-26Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026Insider Monkey · 05-26
The file stays open
87 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice